Description: Each speaker was given 15 minutes to talk and answer questions from the audience.
Brentuximab: A New Treatment Approach for Hodgkin Lymphoma
Speaker:
Serina Patel, MD, FRCPC
Pediatric Haematology/Oncology, Children’s Hospital, London Health Sciences Centre, London, ON
Assistant Professor, Department of Pediatrics, University of Western Ontario, London, ON
Serina Patel is a pediatric haematologist/oncologist at Children’s Hospital, LHSC. Originally from St. John’s, Newfoundland, she attended McGill University for post-secondary studies, where she obtained her Bachelor of Science degree. She returned to Newfoundland for her medical studies and pediatric residency. Following this, she moved to Ottawa to pursue her fellowship in pediatric haematology/oncology. Since the completion of fellowship in 2014, she has worked at Children’s Hospital. She is currently pursuing a Master’s of Science (epidemiology) degree from the University of Ottawa. Her research focus includes the late effects of childhood cancer therapy, specifically with regards to fertility.
Approach to Immunization in Off Therapy Patients
Speaker:
Jeffrey Pernica, MD, FRCPC, DTMH
Head, Division of Infectious Disease, Department of Paediatrics; Associate Professor, McMaster University, Hamilton ON
Jeffrey Pernica completed his paediatric residency at Dalhousie University, his infectious disease fellowship at the University of Ottawa, his tropical medicine training at the Gorgas Memorial Institute, and his epidemiology training at McMaster University. His clinical interests, aside from infectious disease in general, include tropical medicine (he is a member of the Canadian Committee to Advise on Tropical Medicine and Travel) and immunization (he is a member of the Provincial Infectious Disease Advisory Committee on Immunization and runs the Special Immunization Clinic at McMaster Children’s Hospital). His research interests are focused on the optimization of diagnosis and treatment of respiratory infections in high-income countries and of enteric infections in resource-limited settings, primarily via prospective clinical trials. He is an associate professor at McMaster University and the recipient of a Hamilton Health Sciences Early Career Award. He has received research funding from Hamilton Health Sciences, the Physicians’ Services Incorporated Foundation and Grand Challenges Canada.
Dasatinib and High Risk ALL
Speaker :
Vicky Breakey, BSc, MD, MEd, FRCPC
Paediatric Haematologist/Oncologist; Assistant Professor, Department of Paediatrics, McMaster University, Hamilton, ON
Vicky Breakey received her medical degree from the University of Calgary Medical School in Calgary, Alberta. She completed her paediatric residency training and fellowship training in pediatric haematology/oncology at The Hospital for Sick Children in Toronto, Ontario. She pursued her Master of Education degree at the Ontario Institute of Studies in Education at the University of Toronto. In 2011, she joined the Department of Paediatrics at McMaster University as a pediatric haematologist/oncologist.
Dr. Breakey provides clinical care to children with cancer and blood disorders. She is an enthusiastic teacher for patients, parents, medical students, residents and fellows. Her current research interests include clinical studies for children with immune thrombocytopenia, the development of online self-management programs to prepare teens with medical conditions for transition to adult care and nutritional issues for infants with cancer.
CAR-T / Blinotumomab
Speaker:
Sue Zupanec, MN, NP-Paediatrics
Nurse Practitioner, The Hospital for Sick Children, Toronto, ON
Sue Zupanec graduated the Masters of Nursing Program with an Acute Care Nurse Practitioner Certificate from the University of Toronto in April 2002. Since then Sue has worked as a nurse practitioner in the Leukemia/Lymphoma Section, Haematology/Oncology Program at The Hospital for Sick Children. Sue is the current education chair on the Children’s Oncology Nursing Steering Committee.
